EUVIMEDEUVIMED entdecken
Open Access

Acne Incidence and Severity in Transgender Individuals

Courtney A Smith, Oumaima Kaabi, Amita K Manatunga, Timothy L Lash, Michael J Silverberg, Darios Getahun, Suma Vupputuri, Courtney E McCracken, Suephy C Chen, Vin Tangpricha, Michael Goodman, Howa Yeung

JAMA Dermatology · 2026

DOI: 10.1001/jamadermatol.2025.5597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Courtney A Smith und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Transgender Persons, Acne Vulgaris. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIA NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Acne commonly affects transgender individuals prescribed gender-affirming hormone therapy, yet population-level incidence data remain limited.

Objective

To compare the incidence of acne and moderate to severe acne in transgender individuals, including those initiating gender-affirming hormone therapy, with matched cisgender individuals. Design, Setting, and Participants A retrospective matched cohort study of electronic health record data was carried out across 4 Kaiser Permanente health plan regions. Index dates were the earliest documentation of transgender status, ranging from January 2006 to February 2022, with up to 5 years of follow-up. Participants included individuals without baseline acne, transmasculine individuals, and transfeminine individuals matched with cisgender male and female individuals. Analyses were conducted from November 2024 to November 2025. Main Outcomes and Measures The primary outcome was incident acne (first acne-coded visit after the index date). The secondary outcome was moderate to severe acne (incident acne followed by prescription fill for isotretinoin or 30 or more days of oral antibiotics). Exploratory analyses compared acne care utilization by transgender status.

Results

Overall, 280 997 individuals without baseline acne, including 11 234 transmasculine and 9486 transfeminine individuals, were matched to 132 462 cisgender men and 127 815 cisgender women on age, self-reported race and ethnicity (25 340 Asian [9.0%]; 23 234 non-Hispanic Black [8.3%]; 56 876 Hispanic [20.2%]; 153 666 non-Hispanic White [54.7%]; 6989 other [2.5%]), enrollment year, and region. Of these, 12 156 transgender individuals initiated gender-affirming hormone therapy after the index date. The mean (SD) age at index date was 27.7 (10.0) years for transmasculine individuals and 33.2 (13.5) years for transfeminine individuals. Cumulative incidence of acne at 5 years was 15.8% in transmasculine individuals, 3.8% in matched cisgender male individuals, and 10.5% in matched cisgender female individuals and was 6.0% in transfeminine individuals, 2.9% in matched cisgender men, and 8.4% in matched cisgender women. Acne risk in transmasculine individuals was highest in the first year after testosterone initiation (vs matched cisgender male individuals: hazard ratio (HR), 8.29; 95% CI, 7.11-9.68; vs matched cisgender female individuals: HR, 2.63; 95% CI, 2.33-2.97) and remained higher in subsequent years than among cisgender men (HR, 5.29; 95% CI, 4.45-6.28) and cisgender women (HR, 1.69; 95% CI, 1.46-1.96). Acne risk was higher in transfeminine individuals after starting estradiol than cisgender men (HR, 1.56; 95% CI, 1.31-1.84) and lower than cisgender women (HR, 0.53; 95% CI, 0.46-0.62). Moderate to severe acne incidence followed similar patterns. Conclusions and Relevance This study revealed distinct acne incidence patterns in transgender individuals compared with matched cis male and female cohorts. Clinicians should monitor and treat acne in transmasculine individuals prescribed testosterone per clinical guidelines, particularly during the first year. Clinicians should also recognize that acne may develop in transfeminine individuals after estradiol initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsAcne VulgarisHumansMaleFemaleRetrospective StudiesIncidenceAdultSeverity of Illness IndexYoung AdultGender-Affirming ProceduresIsotretinoinAnti-Bacterial AgentsCohort StudiesAdolescent

Substanzen

IsotretinoinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
  • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton.
  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena.
  • Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.

Förderung

  • NIAMS NIH HHS
  • NIA NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Smith, C. A., Kaabi, O., Manatunga, A. K., Lash, T. L., Silverberg, M. J., Getahun, D., Vupputuri, S., McCracken, C. E., Chen, S. C., Tangpricha, V., Goodman, M., & Yeung, H. (2026). Acne Incidence and Severity in Transgender Individuals. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.5597

Vancouver

Smith CA, Kaabi O, Manatunga AK, Lash TL, Silverberg MJ, Getahun D, et al. Acne Incidence and Severity in Transgender Individuals. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2025.5597

BibTeX
@article{Smith2026,
  author = {Smith, Courtney A and Kaabi, Oumaima and Manatunga, Amita K and Lash, Timothy L and Silverberg, Michael J and Getahun, Darios and Vupputuri, Suma and McCracken, Courtney E and Chen, Suephy C and Tangpricha, Vin and Goodman, Michael and Yeung, Howa},
  title = {Acne Incidence and Severity in Transgender Individuals},
  journal = {JAMA Dermatology},
  year = {2026},
  doi = {10.1001/jamadermatol.2025.5597}
}
Kostenlos starten →